Здоровые почки всем и везде: от профилактики и выявления до равного доступа к медицинской помощи

DOI: https://dx.doi.org/10.18565/nephrology.2020.1.18-26

P.K. Li, G. Garcia-Garcia, S.-F. Lui, S. Andreoli, W.W. Fung, A. Hradsky, L. Kumaraswami, V. Liakopoulos, Z. Rakhimova, G. Saadi, L. Strani, I. Ulasi, K. Kalantar-Zadeh

1) Department of Medicine and Therapeutics, Carol & Richard Yu PD Research Centre, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong; 2) Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, University of Guadalajara Health Sciences Center, Guadalajara, Jal., Mexico; 3) Division of Health System, Policy and Management, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong; 4) James Whitcomb Riley Hospital for Children, Indiana University School Of Medicine, Indianapolis, USA; 5) World Kidney Day Office, Avenue des Arts, Brussels, Belgium; 6) Tanker Foundation, Chennai, India; 7) Division of Nephrology and Hypertension, 1st Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; 8) Nephrology Unit, Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, Egypt; 9) Renal Unit, Department of Medicine, College of Medicine, University of Nigeria, Ituku-Ozalla, Enugu, Nigeria; 10) Division of Nephrology and Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Orange, CA, USA
The global burden of chronic kidney disease (CKD) is rapidly increasing with a projection of becoming the 5th most common cause of years of life lost globally by 2040. Aggravatingly, CKD is a major cause of catastrophic health expenditure. The costs of dialysis and transplantation consume up to 3% of the annual healthcare budget in high-income countries. Crucially, however, the onset and progression of CKD is often preventable. In 2020, the World Kidney Day campaign highlights the importance of preventive interventions – be it primary, secondary or tertiary. This complementing article focuses on outlining and analyzing measures that can be implemented in every country to promote and advance CKD prevention. Primary prevention of kidney disease should focus on the modification of risk factors and addressing structural abnormalities of the kidney and urinary tracts, as well as exposure to environmental risk factors and nephrotoxins. In persons with pre-existing kidney disease, secondary prevention, including blood pressure optimization and glycemic control, should be the main goal of education and clinical interventions. In patients with advanced CKD, management of co-morbidities such as uremia and cardiovascular disease is a highly recommended preventative intervention to avoid or delay dialysis or kidney transplantation. Political efforts are needed to proliferate the preventive approach. While national policies and strategies for non-communicable diseases might be present in a country, specific policies directed toward education and awareness about CKD screening, management and treatment are often lacking. Hence, there is an urgent need to increase the awareness of the importance of preventive measures throughout populations, professionals and policy makers.
Ключевые слова: detection, awareness, kidney diseases, prevention


  1. International Society of Nephrology 2019 United Nations High Level Meeting on UHC: Moving Together to Build Kidney Health worldwide. Retrieved 20 July 2019, https://www.theisn.org/images/Advocacy_4_pager_2019_Final_WEB_pagebypage.pdf.

  2. Foreman K.J., Marquez N., Dolgert A., et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052–90.

  3. Essue B.M., Laba T.L., Knaul F., et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. In: Jamison DT, Gelband H, Horton S, et al., eds. Disease Control Priorities Improving Health and Reducing Poverty,. 3 ed. Washington, DC: World Bank;2018:121–43.

  4. Vanholder R., Annemans L., Brown E., et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat. Rev. Nephrol. 2017;13(7):393–409.

  5. Luyckx V.A., Tuttle K.R., Garcia-Garcia G., et al. Reducing major risk factors for chronic kidney disease. Kidney Int. 2017;7(2):71–87.

  6. Luyckx V.A., Tonelli M., Stanifer J.W. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414-22D.

  7. Tonelli M., Muntner P., Lloyd A., et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807–14.

  8. Kalantar-Zadeh K., Fouque D. Nutritional Management of Chronic Kidney Disease. N. Engl. J. Med. 2017;377(18):1765–1776.

  9. United Nations General Assembly. Political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases (2018). Retrieved from https://www.un.org/ga/search/view_doc.asp?symbol=A/73/L.2&Lang=E

  10. Lopez A.D., et al. (2014, October 22). Remembering the forgotten non-communicable diseases. BMC Medicines, 200.

  11. (CDC) Center for Disease Control and Prevention. “Picture of America” (www.cdc.gov/pictureofamerica). At a Glance – Executive Summary. 2017;2019.

  12. Levey A.S., Schoolwerth A.C., Burrows N.R., Williams D.E., Stith K.R., McClellan W. Centers for Disease Control and Prevention Expert Panel. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am. J. Kidney Dis. 2009;53(3):522–35.

  13. Saran R., Robinson B., Abbott K.C., Agodoa L.Y.C., Bragg-Gresham J., Balkrishnan R., Bhave N., Dietrich X., Ding Z., Eggers P.W., Gaipov A., Gillen D., Gipson D., Gu H., et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am. J. Kidney Dis. 2019;73(3S1):A7–A8.

  14. Kovesdy C.P., Furth S.L., Zoccali C. World Kidney Day Steering Committee. Obesity and Kidney Disease: Hidden Consequences of the Epidemic. J. Ren. Nutr. 2017;27(2):75–77.

  15. Tantisattamo E., Dafoe D.C., Reddy U.G., Ichii H., Rhee C.M., Streja E., Landman J., Kalantar-Zadeh K. Current Management of Acquired Solitary Kidney. Kidney International Reports. 2019;4(9):1205–1218.

  16. Webster A.C., Nagler E.V., Morton R.L., Masson P. Chronic Kidney Disease. Lancet. 2017;389(10075):1238–1252.

  17. Koppe L., Fouque D. The Role for Protein Restriction in Addition to Renin-Angiotensin-Aldosterone System Inhibitors in the Management of CKD. Am. J. Kidney Dis. 2019;73(2):248–257.

  18. Rifkin D.E., Coca S.G., Kalantar-Zadeh K. Does AKI truly lead to CKD? J. Am. Soc. Nephrol. 2012;23(6):979–84.

  19. Torres V.E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2012;367(25):2407–18.

  20. Verhave J.C., Troyanov S., Mongeau F., et al. Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care. Clin. J. Am. Soc. Nephrol. 2014;9:713–9.

  21. Chow K.M., Szeto C.C., Kwan B., Leung C.B., Li P.K. Public lacks knowledge on chronic kidney disease: Telephone survey. Hong Kong Med. J. 2014;20:139–44.

  22. Ene-Iordache B., Perico N., Bikbov B. et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study. Lancet. Glob. Health. 2016;4:e307–19.

  23. Li P.K.-T., Weening J.J., Dirks J., et al. A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease. Kidney Int. 2005;(94):s2-7.

  24. Vassalotti J.A., Stevens L.A., Levey A.S. Testing for chronic kidney disease: A position statement from the National Kidney Foundation. Am. J. Kidney Dis. 2007;50:169–80.

  25. Levey A.S., Atkins R., Coresh J., et al. Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247–59.

  26. Crowe E., Halpin D., Stevens P. Guideline Development Group. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ. 2008;337:a1530.

  27. Li P.K.-T., Chow K.M., Matsuo S., et al. Asian Chronic Kidney Disease (CKD) Best Practice Recommendations – Positional Statements for Early Detection of CKD from Asian Forum for CKD Initiatives (AFCKDI). Nephrology (Carlton). 2011;16(7):633–641.

  28. Fink H.A., Ishani A., Taylor B.C., Greer N.L., MacDonald R., Rossini D., Sadiq S., Lankireddy S., Kane R.L., Wilt T.J. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: A systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann. Intern. Med. 2012;156:570–581.

  29. Li P.K.-T., Ng J.K., Cheng Y.L., Kwan T.H., et al. Relatives In Silent Kidney disease Screening study (RISKS): a Chinese cohort study. Nephrology (Carlton). 2017;22 (4):35–42.

  30. Samal L., Linder J.A. The primary care perspective on routine urine dipstick screening to identify patients with albuminuria. Clin. J. Am. Soc. Nephrol. 2013;8(1):131–5.

  31. George C., Mogueo A., Okpechi I., Echouffo-Tcheugui J.B., Kengne A.P. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ. Glob. Health. 2017;2(2):e000256.

  32. Gonzalez-Quiroz M., Nitsch D., Hamilton S., O’Callaghan Gordo C., Saran R., Glaser J., Correa-Rotter R., Jakobsson K., Singh A., Gunawardena N., Levin A., Remuzzi G., Caplin B., Pearce N. DEGREE Study Steering Committee. Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE). BMJ Open. 2019;9:e031169.

  33. Boulware L.E., Jaar B.G., Tarver-Carr M.E., Brancati F.L., Powe N.R. Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA. 2003;290:3101–14.

  34. Go D.S., Kim S.H., Park J., Ryu D.R., Lee H.J., Jo M.W. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea. Nephrology (Carlton). 2019;24(1):56–64.

  35. Komenda P., Ferguson T.W., Macdonald K., et al. Cost-effectiveness of primary screening for CKD: A systematic review. Am. J. Kidney Dis. 2014;63:789–97.

  36. Hwang S.J., Tsai J.C., Chen H.C. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton). 2010;15(2):3–9.

  37. Almaguer M., Herrera R., Alfonso J., Magrans C., Mañalich R., Martínez A. Primary health care strategies for the prevention of end-stage renal disease in Cuba. Kidney Int. Suppl. 2005;97:S4-10.

  38. Alamaguer-Lopez M., Herrera-Valdez R., Diaz J., Rodriguez O. Integration of chronic kidney disease prevention into noncommunicable disease programs in Cuba. In G. Garcia-Garcia, L.Y. Agodoa, & K.C. Norris (Eds.), Chronic Kidney Disease in Disadvantaged Populations, 2017. (pp. 357-365). London: Elsevier Inc.

  39. U.S. Department of Health and Human Services. Advancing American Kidney Health., 2019. Accessed Sept. 26, 2019 https://aspe.hhs.gov/pdf-report/advancing-american-kidney-health

  40. U.S. Department of Health and Human Services. The Special Diabetes Program for Indians. Estimates of Medicare savings., 2019. Accessed Sept. 26, 2019 https://aspe.hhs.gov/pdf-report/special-diabetes-program-indians-estimates-medicare-savings

  41. Bello A.K., Nwankwo E., El Nahas A.M. Prevention of chronic kidney disease: a global challenge. Kidney Int. Suppl. 2005;98:S11-17.

  42. James M.T., Hemmelgarn B.R., Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010; 375(9722):1296–1309.

  43. Cortés-Sanabria L., Cabrera-Pivaral C.E., Cueto-Manzano A.M., Rojas-Campos E., Barragán G., Hernández-Anaya M., Martínez-Ramírez H.R. Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial. Am. J. Kidney Dis. 2008;51(5):777–788.

  44. Martínez-Ramírez H.R., Jalomo-Martínez B., Cortés-Sanabria L., Rojas-Campos E., Barragán G., Alfaro G., Cueto-Manzano A.M. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am. J. Kidney Dis. 2006;47(1)78–87.

  45. Cueto-Manzano A.M., Martínez-Ramírez H.R., Cortes-Sanabria L., Rojas-Campos E. CKD screening and prevention strategies in disadvantaged populations. The role of primary health care professionals. In G. Garcia-Garcia, L.Y. Agodoa, & K.C. Norrris (Eds.). Chronic Kidney Disease in Disadvantaged Populations. 2017 (pp. 329-335).London: Elsevier, Inc.

  46. Tapia-Conyer R., Gallardo-Rincon H., Betancourt-Cravioto M. Chronic kidney disease in disadvantaged populations: Online educational programs for NCD prevention and treatment. In G. Garcia-Garcia, L.Y. Agodoa, & K.C. Norris (Eds.). Chronic Kidney Disease in Disadvantaged Populations. 2017 (pp. 337-345). London: Elsevier, Inc.

  47. Bello A.K., Levin A., Manns B.J., Feehally J., Drueke T., Faruque L., Hemmelgarn B.R., Kernahan C., Mann J., Klarenbach S., Remuzzi G., Tonelli M. Kidney Health for Life Initiative.Effective CKD care in European countries: challenges and opportunities for health policy. Am. J. Kidney Dis. 2015;65(1):15–25.

  48. Sharif M.U., Elsayed M.E., Stack A.G. The global nephrology workforce: emerging threats and potential solutions! Clin Kidney J. 2016;9(1):11–22.

  49. Naicker S., Eastwood J.B., Plange-Rhule J., Tutt R.C. Shortage of healthcare workers in sub-Saharan Africa: a nephrological perspective. Clin Nephrol. 2010;74(1):S129–133.

  50. Cusumano A.M., Rosa-Diez G.J., Gonzalez-Bedat M.C. Latin American Dialysis and Transplant Registry: Experience and contributions to end-stage renal disease epidemiology. World J. Nephrol. 2016;5(5):389–397.

  51. Feehally J., Brusselmans A., Finkelstein F.O., Harden P., Harris D., Manuzi G., Naicker S., Tonelli M., Cameron H. Improving global health: measuring the success of capacity building outreach programs: a view from the International Society of Nephrology. Kidney Int. Suppl. 2016;6(2):42–51.

  52. Harris D.C., Dupuis S., Couser W.G., Feehally J. Training nephrologists from developing countries: does it have a positive impact? Kidney Int. Suppl. 2012;2(3):275–278.

  53. Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel. Ann Intern. Med. 1994;121(1):62–70.

  54. Garcia-Garcia G., Martinez-Castellanos Y., Renoirte-Lopez K., Barajas-Murguia A., de la Torre-Campos L., Becerra-Muñoz L.E., Gonzalez-Alvarez J.A., Tonelli M. Multidisciplinary care for poor patients with chronic kidney disease in Mexico. Kidney Int. Suppl. (2011). 2013;3(2):178–183.

  55. Stanifer J.W., Von Isenburg M., Chertow G.M., Anand S. Chronic kidney disease care models in low- and middle-income countries: a systematic review. BMJ Glob. Health. 2018;3(2):e000728.

  56. Narva A.S., Norton J.M., Boulware L.E. Educating Patients about CKD: The Path to Self-Management and Patient-Centered Care. Clin. J. Am. Soc. Nephrol. 2016;7;11(4):694–703.

  57. Schatell D. Web-based kidney education: supporting patient self-management. Semin. Dial. 2013;26(2):154–8.

Об авторах / Для корреспонденции

Philip Kam-Tao Li – MD FRCP FACP, Department of Medicine and Therapeutics Prince of Wales Hospital, Chinese University of Hong Kong, 30–32 Ngan Shing Street, Shatin, New Territories; Hong Kong, China. E-mail: philipli@cuhk.edu.hk

Похожие статьи

Бионика Медиа